ACADIA Pharmaceuticals Inc. (ACAD): Price and Financial Metrics
ACAD Stock Summary
- The ratio of debt to operating expenses for Acadia Pharmaceuticals Inc is higher than it is for about only 9.44% of US stocks.
- ACAD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 10.95% of US stocks.
- With a year-over-year growth in debt of 610.82%, Acadia Pharmaceuticals Inc's debt growth rate surpasses 97.34% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Acadia Pharmaceuticals Inc, a group of peers worth examining would be PACB, EPZM, TRVN, JG, and FORM.
- Visit ACAD's SEC page to see the company's official filings. To visit the company's web site, go to www.acadia-pharm.com.
ACAD Stock Price Chart Interactive Chart >
ACAD Price/Volume Stats
| Current price | $48.97 | 52-week high | $58.72 |
| Prev. close | $47.31 | 52-week low | $30.02 |
| Day low | $47.13 | Volume | 993,200 |
| Day high | $49.37 | Avg. volume | 903,613 |
| 50-day MA | $52.02 | Dividend yield | N/A |
| 200-day MA | $47.78 | Market Cap | 7.79B |
ACADIA Pharmaceuticals Inc. (ACAD) Company Bio
Acadia Healthcare Company is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders. The company was founded in 1993 and is based in San Diego, California.
Latest ACAD News From Around the Web
Below are the latest news stories about Acadia Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACAD as an investment opportunity.
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2020 Results - Earnings Call TranscriptACADIA Pharmaceuticals Inc. (ACAD) Q4 2020 Earnings Conference Call February 24, 2021 4:30 p.m. ET Company Participants Mark Johnson - VP, IR Steve Davis - CEO Elena Ridloff - CFO Amanda Morgan - Chief Revenue and Customer Officer Charmaine Lykins - Global Product Planning and Chief Marketing Officer Serge Stankovic... |
ACADIA Pharmaceuticals Inc. 2020 Q4 - Results - Earnings Call PresentationThe following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with their 2020 Q4 earnings call.... |
ROCE Insights For ACADIA PharmaceuticalsACADIA Pharmaceuticals (NASDAQ:ACAD) reported Q4 sales of $121.01 million. Earnings fell to a loss of $67.16 million, resulting in a 21.81% decrease from last quarter. In Q3, ACADIA Pharmaceuticals brought in $120.58 million in sales but lost $85.90 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, ACADIA Pharmaceuticals posted an ROCE of -0.11%. Keep in mind, while ROCE is a good measure of a company's recent performance, ... |
A Preview Of ACADIA Pharmaceuticals's EarningsOn Wednesday, February 24, ACADIA Pharmaceuticals (NASDAQ:ACAD) will release its latest earnings report. Check out Benzinga's preview to understand the implications. What Are Earnings, Net Income, And Earnings Per Share? Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS. Earnings And Revenue Wall Street expects an EPS loss of $0.47 and sales around $123.20 million. ACADIA Pharmaceuticals EPS in the same period a year ago totaled $0.34. Revenue was $98.33 million. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Analysts who cover this company will publish forward-looking estimates of its revenue and... |
Announcing: ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Increased An Energizing 191% In The Last Five YearsThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if... |
ACAD Price Returns
| 1-mo | 1.91% |
| 3-mo | -13.57% |
| 6-mo | 28.60% |
| 1-year | 14.58% |
| 3-year | 113.10% |
| 5-year | 155.72% |
| YTD | -8.40% |
| 2020 | 24.96% |
| 2019 | 164.56% |
| 2018 | -46.30% |
| 2017 | 4.40% |
| 2016 | -19.10% |
Continue Researching ACAD
Here are a few links from around the web to help you further your research on Acadia Pharmaceuticals Inc's stock as an investment opportunity:Acadia Pharmaceuticals Inc (ACAD) Stock Price | Nasdaq
Acadia Pharmaceuticals Inc (ACAD) Stock Quote, History and News - Yahoo Finance
Acadia Pharmaceuticals Inc (ACAD) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...